Intratumoural administration of dendritic cells: hostile environment and help by gene therapy

Bibliography

• SIMONSEN M: Changing role for cardiac surgery as use of stents continues growth.Cardiovasc. Device Update (2003) 9:1–7.
   Google Scholar
• TOPOL EJ, SERRUYS PW: Frontiers in interventional cardiology. Circulation (1998) 98:1802–1820.
   PubMed Web of Science ®Google Scholar
• SERRUYS PW, FOLEY DP, SUTTORP MJ et al.: A randomized comparison of the value of additional stenting after optimal balloon angioplasty for long coronary lesions. J. Am. Coll. CardioL (2002) 39:393–399.
   PubMed Web of Science ®Google Scholar
• VAN DEN BRAND MJ, RENSING BJ,MOREL MA et aL: The effect of completeness of revascularization on event-free survival at one-year in the ARTS trial. J. Am. Coll. CardioL (2002) 39:559–564.
   PubMed Web of Science ®Google Scholar
• NAKATANI M, TAKEYAMA Y, SHIBATA M et al.: Mechanisms of restenosis after coronary intervention. Difference between plain old balloon angioplasty and stenting. Cardiovasc. Pathol (2003) 12:40–48.
   Google Scholar
• GOLDBERG SL, LOUSSARARIAN A, DE GREGORIO J, DI MARIO C, ALBIERRO R, COLOMBO A: Predictors of diffuse and aggressive intrastent restenosis. J. Am. Coll. Cardiol (2001) 37:1019–1025.
   PubMed Web of Science ®Google Scholar
• YLA-HERTTUALA S, MARTIN JF: Cardiovascular gene therapy. Lancet (2000) 355:213–222.
   PubMed Web of Science ®Google Scholar
• LIBBY P, SCHWARTZ D, BOGI E, TANAKA H, CLINTON SK: A cascade model for restenosis: special case of atherosclerosis progression. Circulation (1992) 86:47–52.
   PubMed Web of Science ®Google Scholar
• CLOWES AW, CLOWES MM, FINGERLE J, REIDLY MA: Regulation of smooth muscle cell growth in injured artery. Cardiovasc. Pharmacol (1989) 14\(Suppl. 6):S12–S15.
   Google Scholar
• FINGERLE J, JOHNSON R, CLOWES AW, MAJESKY MW, REIDY MA: Roles of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery. Proc. Natl Acad. Sci. USA (1989) 86:8412–8416.
   PubMed Web of Science ®Google Scholar
• NIKKARI ST, CLOWES AW: Restenosis after vascular reconstruction. Ann. Med. (1994) 26:95–100.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ SM, DE BLOIS D, O'BRIEN RM: The intima - soil for restenosis and atherosclerosis. Circ. Res. (1997) 77:445–465.
   Web of Science ®Google Scholar
• AGATA J, ZHANG JJ, CHAO L: Adrenomedullin gene delivery inhibits neointima formation in rat artery after ballon angioplasty. Regul Rep. (2003) 112:115–120.
   PubMedGoogle Scholar
• KIPSHIDZE N, MOSES J, SHANKAR LR et al.: Perspectives on antisense therapy for the prevention of restenosis. Curr. Opin. MoL Ther. (2001) 3:265–277.
   PubMed Web of Science ®Google Scholar
• KIPSHIDZE N, IVERSEN P, KEANE Eet al.: Complete vascular healing and sustained suppression of neointimal thickening after local delivery of advanced c-myc antisense at six months follow-up in a rabbit balloon injury model. Cardiovasc. Radiat. Med. (2002) 3:26–30.
   Google Scholar
• GEORGE SJ, ANDELINI GD, CAPOGROSSI MC et al.: Wild-type p53 gene transfer inhibits neointima formation in human saphenous vein by modulation of smooth muscle cell migration and induction of apoptosis. Gene Ther. (2001) 8:668–676.
   PubMed Web of Science ®Google Scholar
• MURAKAMI H, YAYAMA K, MIAO RQ et al.: Kallikrein gene delivery inhibits vascular smooth muscle cell growth and neointima formation in the rat artery after balloon angioplasty. Hypertension (1999) 34:164–170.
   PubMed Web of Science ®Google Scholar
• STEG GP, TAHLIL O, AUBAILLY N et al.: Reduction of restenosis after angioplasty in an atheromatous rabbit model by suicide gene therapy. Circulation (1997) 96:408–411.
   PubMed Web of Science ®Google Scholar
• HARELL RL, RAJANAYAGAM S, DOANES AM et al.: Inhibition of vascular smooth muscle cell proliferation and neointimal accumulation by adenovirus-mediated gene transfer of cytosine deaminase. Circulation (1997) 96:621–627.
   PubMed Web of Science ®Google Scholar
• ZOLDHELIY P, MCNATT J, SHELAT H et al.: Thromboresistence of balloon-injured porcine carotid arteries after local gene transfer of human tissue factor pathway inhibitor. Circulation (2000) 101:289–295.
   PubMed Web of Science ®Google Scholar
• VAN BELLE E, TIO FO, CHEN D et al.: Passivation of metallic stents after arterial gene transfer of phVEGF 165 inhibits thrombus formation and intimal thickening. J. Am. Coll Cardiol. (1997) 29:1371–1379.
   PubMed Web of Science ®Google Scholar
• YOON J, WU CJ, HOMME J et al.: Local delivery of nitric oxide from an eluting stent to inhibit neointimal thickening in a porcine coronary injury model. Yonsei Med. J. (2002) 43:242–251.
   PubMed Web of Science ®Google Scholar
• FELDMAN MD, BO SUN, KOCI B et al.: Stent-based gene therapy. J. Long Term Eft: Med. Implants (2000) 10:47–68.
   PubMed Web of Science ®Google Scholar
• ZAMECNIK P, STEPHENSON M: Inhibition of Rous sarcoma virus replication and cell transformation by a specific deoxyoligonucleotide. Proc. Nail. Acad. Sci. USA (1978) 75:280–284.
   PubMed Web of Science ®Google Scholar
• ••Describes the first attempt to inhibit geneexpression using antisense ODNs.
   Google Scholar
• WANG A, CREASY A, LARDNER M et al.: Molecular cloning of the complementary DNA for human tumor necrosis factor. Science (1985) 228:149–154.
   PubMed Web of Science ®Google Scholar
• MORISHITA R, KANEDA Y, OGIHARAT: Therapeutic potential of oligonucleotide-based therapy in cardiovascular disease. BioD rugs (2003) 17(6):383–389.
   PubMed Web of Science ®Google Scholar
• HELENE C, TOULME JJ: Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochem. Biophys. Acta (1990) 1049:99–125.
   PubMed Web of Science ®Google Scholar
• STEIN CA, CHENG YC: Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science (1993) 261:1004–1012.
   PubMed Web of Science ®Google Scholar
• SHI Y, FAD A, GALLEON A et aL: Transcatheter delivery of c-myc antisense oligomers reduced neointimal formation in a porcine model of coronary artery balloon injury. Circulation (1994) 90:944–951.
   PubMed Web of Science ®Google Scholar
• ••One of the first papers to discuss theefficacy of local c-myc antisense delivery to prevent intimal hyperplasia in vivo.
   Google Scholar
• BENNETT MR, SCHWARTZ SM: Antisense therapy for angioplasty restenosis: some critical considerations. Circulation (1995) 92:1981–1993.
   PubMed Web of Science ®Google Scholar
• STEIN CA:. TOKINSON JL, YAKUBOV L: Phosphorothioate oligodeoxynucleotides antisense inhibitors of gene expression? Pharmacol Ther. (1991) 52:365–384.
   Google Scholar
• BOLZIAU C, KURFIST R, CAZENAVE C, ROIG V, THOUNG NT, TOULME JJ: Inhibition of translation initiation by antisense oligonucleotides via an RNAase independent mechanism. NudeicAcidRes. (1991) 19:1113–1119.
   Google Scholar
• •Describes possible mechanism of the antisense inhibition through steric interference.
   Google Scholar
• GOODCHILD J: Inhibition of gene expression by oligonucleotides. In: Oligonucleotides: Antisense Inhibitors of Gene Expression. Cohen J (Ed.), Macmillan Press, London, UK (1989):53–77.
   Google Scholar
• KOZAK M: Influences of mRNA secondary structure on inhibition by eucaryotic ribosome. Proc. Natl. Acad. Sci. USA (1996) 83:2850–2854.
   Google Scholar
• WAGNER R, NISHIKURA K: Cell cycle expression of RNA duplex unwinding activity in cells. MoL Cell. Biol. (1988) 8:770–777.
   PubMed Web of Science ®Google Scholar
• DASH P, LOTAN L, KNAPP M, KANDEL ER, GOELET P: Selective elimination of mRNA in vivo: complementary oligodeoxynucleotides promote RNA degradation by RNAse-H like activity. Proc. Natl. Acad. Sci. USA (1987) 84:7896–7900.
   PubMed Web of Science ®Google Scholar
• DAGLE JM, WALDER JA, WEEKS DL: Target degradation of mRNA in Xenopus oocytes and embryos directed by modified oligonucleotides: studies of An2 and cyclin in embryogenesis. Nucleic Acid Res. (1990) 18:4751–4757.
   PubMed Web of Science ®Google Scholar
• MCMANNAWAY ME, NECKERS LM, LOKE SL et al.: Tumor-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide. Lancet (1990) 335:808–811.
   PubMed Web of Science ®Google Scholar
• BURGESS TL, FISHER EF, ROSS SL et al.: The antiproliferative effect of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a non antisense mechanism. Proc. NatL Acad. Sci. USA (1995) 92(9):4051–4055.
   PubMed Web of Science ®Google Scholar
• SIMONS M, ROSENBURG RD: Antisense non-muscle, myosin, heavy chain and c-myb oligonucleotides suppress smooth muscle cell proliferation in vitro. Circ. Res. (1992) 70:835–843.
   PubMed Web of Science ®Google Scholar
• GUNN J, HOLT CM, FRANCIS SE et aL:The effect of oligonucleotides to c-myb on vascular smooth muscle cell proliferation and neointima formation after porcine coronary angioplasty. Circ. Res. (1997) 80:520–531.
   PubMed Web of Science ®Google Scholar
• SPEIR E, EPSTEIN SE: Inhibition of smooth muscle cell proliferation by an antisense deoxyoligonucleotide targeting the mRNA coding proliferating cell nuclear antigen. Circulation (1992) 86:538–547.
   PubMed Web of Science ®Google Scholar
• SIMONS M, EDELMAN ER, ROSENBERG RD: Antisense PCNA oligonucleotides inhibit neointimal hyperplasia in a rat carotid artery injury model. J. Clin. Invest. (1994) 93:2351–2356.
   PubMed Web of Science ®Google Scholar
• SUGIKI H: Suppression of vascular smooth muscle cell proliferation by an antisense oligonucleotide against PDGF receptor. Hokkaido Igaku Zasshi (1995) 70(3):485–495.
   PubMedGoogle Scholar
• HANNA AK, FOX JC, NECKLIS DG et aL: Antisense basic fibroblast growth factor gene transfer reduces neointimal thickening after arterial injury. J. Vasc. Surg. (1997) 25(2):320–325.
   PubMed Web of Science ®Google Scholar
• MANDIYAN S, SCHUMACHER C, CIOFFI C et aL: Molecular and cellular characterization of baboon C-Raf as target for antiproliferative effects of antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. (1997) 7(6):539–548.
   PubMedGoogle Scholar
• BIRO S, FU YM, YU 2X, EPSTEIN SE: Inhibitory effects of oligodeoxynucleotides targeting c-myc RNA on smooth muscle cell proliferation and migration. Proc. NatL Acad. Sci. USA (1993) 90:654–658.
   PubMed Web of Science ®Google Scholar
• DAUM T, ENGELS JW, MAG M et al.: Antisense deoxynucleotide: inhibitor of splicing of mRNA of human immunodeficiency virus. Int. Virology (1992) 89:7031–7035.
   Google Scholar
• SIMONS M, EDELMAN ER, DEKEYSER J-L, LANGER R, ROSENBERG RD: Antisense c-myb oligonucleotides inhibits intimal arterial smooth muscle cell accumulation in vivo. Nature (1992) 359:67–70.
   PubMed Web of Science ®Google Scholar
• MORISHITA R, GIBBONS GH, ELLISON KE et al.: Single intraluminal delivery of antisense cdc kinase PCNA results in chronic inhibition of neointimal hyperplasia. Proc. NatL Acad. Sci. USA (1993) 90:8474–8478.
   PubMed Web of Science ®Google Scholar
• BAYEVER E, IVERSEN PL, BISHOP MR et al.: Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a Phase I trial. Antisense Res. Dev. (1993) 4(4):383–390.
   Google Scholar
• AGROTIS A, KANELLAKIS P, KOSTOLIAS G et al.: Proliferation of neointimal smooth muscle cells after arterial injury: dependency on interaction between fibroblast growth factor receptor-2 and fibroblast growth factor-9. J. Biol. Chem. (2004) 279(40):42221–42229.
   PubMed Web of Science ®Google Scholar
• BLINDT R, BOSSERHOFF AK, DAMMERS J et al.: Downregulation of N-cadherin in the neointima stimulates migration of smooth muscle cells by RhoA deactivation. Cardiovasc. Res. (2004) 62(1):212–222.
   PubMed Web of Science ®Google Scholar
• SUMMERTON J, STEIN D, HUANG B, MATTHEWS P, WELLER D, PARTRIDGE M: Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems. Antisense Nucleic Acid Drug Dev. (1997) 7:63–70.
   PubMedGoogle Scholar
• ABE J, ZHOU W, TAGUCHI J: Suppression of neointimal smooth muscle cell accumulation in vivo by antisense cdc2 and cdk2 oligonucleotides in rat carotid artery. Biochem. Biophys. Commun. (1994) 198:16–24.
   PubMed Web of Science ®Google Scholar
• ROBINSON KA, CHRONOS NA, SCHIEFFER E et al.: Endoluminal local delivery of PCNA/cdc2 antisense oligonucleotides by porous balloon catheter does not affect neointima formation or vessel size in the pig coronary artery model of post angioplasty restenosis. Cathet. Cardiovasc. Diagn. (1997) 41:348–353.
   PubMedGoogle Scholar
• SCHMIDT A. SINDERMANN J, PEYMAN A et al.: Sequence specific antiproliferative effects of antisense and end-capping modified antisense oligodeoxynucleotides targeted against the 5'-terminus of Basic-fibroblast growth factor mRNA in coronary smooth muscle cells. Eur. j Biochem. (1997) 248(2) :543–549.
   Google Scholar
• TANAKA S, AMLING M, NEFF Let al.:c-cbl downstream of c-src in a signaling pathway necessary for bone resorption. Nature (1996) 383:528–531.
   Google Scholar
• PEYMAN A, HELSBERG M, KRETZSCHMAR G, MAG M, RYTE A, UHLMANN E: Nuclease stability as dominant factor in the antiviral activity of oligonucleotides directed again HSV-1 IEI10. Antiviral Res. (1997) 33:135–139.
   PubMed Web of Science ®Google Scholar
• STEIN D, FOSTER E, HUANG SB, WELLER D, SUMMERTON J: A specificity comparison of four antisense types: morpholino, 2-0 methyl RNA, DNA and phosphorothioate DNA. Antisense Nucleic Acid Drug Dev. (1997) 7:151–157.
   PubMedGoogle Scholar
• HOLT JT, RENDER RL, NELHUS AW: An oligomer complementary to c-myc RNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation. Mol. Cell. Biol. (1988) 8:963–973.
   PubMed Web of Science ®Google Scholar
• VILLA AE, GUZMAN LA, POPTIC EJ et al.: Effects of antisense c-myb oligonucleotides on vascular smooth muscle cell proliferation and response to vessel wall injury. Circ. Res. (1995) 76:505–513.
   PubMed Web of Science ®Google Scholar
• MULLER DW: The role of proto-oncogenes in coronary restenosis. Prog. Cardiovasc. Dis. (1997) 40(2):117–128.
   PubMed Web of Science ®Google Scholar
• WICKSTROM E: Antisense c-myc inhibition of lymphoma growth. Antisense Nucleic Acid Drug Dev. (1997) 7(3):225–228.
   PubMedGoogle Scholar
• CAZENAVE C, LOREAU N, THUONG NT, TOULME JJ: Enzymatic amplification of translation inhibition of rabbit beta-globin mRNA mediated by anti-messenger oligodeoxynucleotides covalently linked to intercalating agents. Nucleic Acid Res. (1995) 15(12):4717–4736.
   Google Scholar
• SHAW JP, KENT K, BIRD J, FISHBACK J, FROEHLER BF: Modified deoxyoligonucleotide stable to exonuclease degradation in serum. Nucleic Acids Res. (1991) 19:747–750.
   PubMed Web of Science ®Google Scholar
• OTT J, ECKSTEIN F: Protection of oligonucleotide primers against degradation by DNA polymerase I. Biochemistry (1987) 26(25):8237–8241.
   PubMed Web of Science ®Google Scholar
• HOKE GD, DRAPER K, FREIER SM et aL: Effect of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection. Nucleic Acid Res. (1991) 20:5743–5748.
   Google Scholar
• CORNISH KG, IVERSEN PL, SMITH L, ARNESON M, BAYEVER E: Cardiovascular effects of a phosphorothioate oligonucleotide with sequence antisense to p53 in the conscious rhesus monkey. PharmacoL Commun. (1993) 3:239–247.
   Google Scholar
• GALBRAITH -WM, HOBSON WC, GICLAS PC, SCHECHTER PJ, AGRAWAL S: Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Dev. (1994) 4:201–206.
   PubMedGoogle Scholar
• HENRY SP, BOLTE H, AULETTA C, KORNBURST DJ: Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four week study in cynomolgus monkeys. Toxicology (1997) 120:145–155.
   PubMed Web of Science ®Google Scholar
• IVERSEN PL, CORNISH KG, IVERSEN LJ, MATA JE, BYLUND DB: Bolus intravenous injection of phosphorothioate oligonucleotides causes hypotension by acting as al-adrenergic receptor antagonists. Toxicol. Appl. PharmacoL (1999) 160:289–296.
   PubMed Web of Science ®Google Scholar
• HEDIN U, WAHLBERG E: Gene therapy and vascular disease: potential applications in vascular surgery. Eur. j Vasc. Endovasc. Surg. (1997) 13:101–111.
   PubMed Web of Science ®Google Scholar
• KIPSHIDZE NN, IVERSEN P, KIM HS et al.: Advanced c-myc antisense (AVI-4126)-eluting phosphorylcholine-coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model. Catheter Cardiovasc. Interv. (2004) 61(4):518–527.
   PubMed Web of Science ®Google Scholar
• ZHANG XX, CUI CC, XU XG, HU XS, FANG WH, KUANG BJ: In vivo distribution of c-Myc antisense oligonucleotides local delivered by gelatin-coated platinum-iridium stent in rabbits and its effect on apoptosis. Chin. Med. J. (EngL) (2004) 117(2):258–263.
   PubMed Web of Science ®Google Scholar
• PORTER TR, IVERSEN PL, LI S, XIE F:Interaction of diagnostic ultrasound with synthetic oligonucleotide-labeled perfluorocarbon-exposed sonicated dextrose albumin microbubbles. J. Ultrasound Med. (1996) 15:577–584.
   PubMed Web of Science ®Google Scholar
• MANN MJ, WHITTEMORE AD, DONALDSON MC et aL: Ex vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet (1999) 354(9189):1493–1498.
   PubMed Web of Science ®Google Scholar
• KUTRYK MJ, FOLEY DP, VAN DEN BRAND M et aL: Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial. J. Am. Coll. CardioL (2002) 39(2):281–287.
   PubMed Web of Science ®Google Scholar
• •ITALICS trial result. This was the first clinical experience with local delivery of an antisense compound in coronary arteries using a local delivery catheter.
   Google Scholar
• HUDZIAK RM, BAROFSKY E, BAROFSKY DF et al.: Resistance of morpholino phosphorodiamiclate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev. (1996) 6:267–272.
   PubMedGoogle Scholar
• HUDZIAK RM, SUMMERTON J, WELLER DD, IVERSEN PL: Antiproliferative effects of steric blocking phosphorodiamidate Morpholino antisense agents directed against c-myc. Antisense Nucleic Acid Drug Dev. (2000) 10:163–176.
   PubMedGoogle Scholar
• DANI C, BLANCHARD JM, PIECHACZYK M, EL SABOUTY S, MARTY L, JEANTEUR P: Extreme instability of myc mRNA in normal and transformed human cells. Proc. Nail. Acad. Sci. USA (1984) 81:7046–7050.
   PubMed Web of Science ®Google Scholar
• KIPSHIDZE N, KEANE E, STEIN D et al.: Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. Catheter. Cardiovasc. Interv. (2001) 54:247–256.
   PubMed Web of Science ®Google Scholar
• KIPSHIDZE NN, KIM H-S, IVERSEN P et al.: Intramural delivery of advanced antisense oligonucleotides with infiltrator cathetor inhibits c-myc expression and intimal hyperplasia in the porcine stent restenosis model. J. Am. Coll. CardioL (2002) 39(10):1686–1691.
   PubMed Web of Science ®Google Scholar
• SHEPPARD R, EISENBERG MJ: Intracoronary radiotherapy for restenosis. N EngL J. Med. (2001) 344(4):295–297.
   PubMed Web of Science ®Google Scholar
• HERDEG C, OBERHOFF M, BAUMBACH A et aL: Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J. Am. Coll. Cardiol. (2000) 35(7):1969–1976.
   PubMed Web of Science ®Google Scholar
• KIPSHIDZE NN, PORTER TR, DANGAS G et al.: Systemic targeted delivery of antisense with perflourobutane gas microbubble carrier reduced neointimal formation in the porcine coronary restenosis model. Cardiovasc. Radiat. Med. (2003) 4(3):152–159.
   PubMedGoogle Scholar
• KIPSHIDZE NN, OVERLIE P, DUNLAP T et al.: First human experience with local delivery of novel antisense AVI-4126 with infiltrator catheter in de novo native and restenotic coronary arteries: six-month clinical and angiographic follow-up from AVAIL study. Circulation (2004) 110(17):III-757. Abstract.
   Google Scholar
• •AVAIL trial result.
   Google Scholar